Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Msci Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.17 (market cap $39.89B), while Msci Inc trades at $613.7 (market cap $44.02B). The key difference: Alnylam Pharmaceuticals, Inc. and Msci Inc are close in size by market cap, and Msci Inc pays a 1.36% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MSCI | |
|---|---|---|
Market Cap | $39.89B | $44.02B |
Sector | Health | Financials |
52-Week High | $491.22 | $643.83 |
52-Week Low | $278.09 | $511.84 |
Enterprise Value | $38.15B | $50.19B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MSCI trades at $604.71, up 0.23% today, with a bullish technical signal and strong support at $595. The stock shows robust fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.74%, though valuations are elevated with a P/E of 34.54. Recent news highlights strategic partnerships with UBS and acquisitions to enhance its private markets and climate risk capabilities.
Outlook is positive given consistent earnings beats and a consensus price target of $718.14, but risks include high debt levels and reliance on market data demand. Analyst sentiment is strongly bullish with 73% buy ratings, supporting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
